Zidovudine azido-reductase in human liver microsomes: Activation by ethacrynic acid, dipyridamole, and indomethacin and inhibition by human immunodeficiency virus protease inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 7, 1998, Pages 1654-1658

  Fayz, Shirin ^a   Inaba, T ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3' AMINO 3' DEOXYTHYMIDINE; ALPHA NAPHTHOFLAVONE; CAFFEINE; CHLORAMPHENICOL; CHLORZOXAZONE; COUMARIN; CYCLOSPORIN A; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 REDUCTASE; DIPYRIDAMOLE; DRUG METABOLITE; ETACRYNIC ACID; FLAVINE ADENINE NUCLEOTIDE; FLAVINE MONONUCLEOTIDE; FLUCONAZOLE; FLUOROURACIL; INDINAVIR; INDOMETACIN; KETOCONAZOLE; METYRAPONE; NAPROXEN; PARACETAMOL; PROTEINASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RIBOFLAVIN; RITONAVIR; SAQUINAVIR; UNINDEXED DRUG; ZIDOVUDINE; ZIDOVUDINE GLUCURONIDE;

ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MICHAELIS CONSTANT; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; THIN LAYER CHROMATOGRAPHY;

EID: 0031808785     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.7.1654     Document Type: Article

References (39)

1. Barry, M., J. Howe, D. Back, A. Breckenridge, R. Brettle, R. Mitchell, N. J. Beeching, and F. J. Nye. 1993. The effects of indomethacin and naproxen on zidovudine pharmacokinetics. Br. J. Clin. Pharmacol. 36:82-85.
2. Bertz, R. J., and G. R. Granneman. 1997. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32:210-258.
3. Betageri, G. V., J. Szebeni, K. Hung, S. S. Patel, L. M. Wahl, M. Corcoran, and J. N. Weinstein. 1990. Effect of dipyridamole on transport and phosphorylation of thymidine and AZT in human monocyte/macrophages. Biochem. Pharmacol. 40:867-870.
4. Blum, M. R., S. H. T. Liao, S. S. Good, and P. DeMiranda. 1988. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85(Suppl. 2A):189-194.
5. Burger, D. M., P. L. Meenhorst, C. H. W. Koks, and J. H. Beijnen. 1993. Drug interactions with zidovudine. AIDS 7:445-460.
6. Burger, D. M., P. L. Meenhorst, C. H. W. Koks, and J. H. Beijnen. 1993. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob. Agents Chemother. 37:1426-1431.
7. Collier, A. C., R. W. Coombs, D. A. Schoenfeld, R. L. Bassett, J. Timpone, A. Baruch, M. Jones, K. Facey, C. Whitacre, V. J. McAuliffe, H. M. Friedman, T. C. Merigan, R. C. Reichman, C. Hooper, and L. Corey. 1996. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N. Engl. J. Med. 334:1011-1017.
8. Cretton, E. M., M. Y. Xie, R. J. Bevan, R. F. Schinazi, and J. P. Sommadossi. 1991. Catabolism of AZT in hepatocytes and liver microsomes with evidence of formation of 3′-amino-3′-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Mol. Pharmacol. 39:258-266.
9. Cretton, E. M., R. F. Schinazi, H. M. McClure, D. C. Anderson, and J. P. Sommadossi. 1991. Pharmacokinetics of AZT and its catabolites and interactions with probenecid in rhesus monkeys. Antimicrob. Agents Chemother. 35:801-807.
10. Cretton, E. M., X. R. Pan-Zhou, P. Maurel, and J. P. Sommadossi. 1994. Reduction of AZT in human liver microsomes. Clin. Pharmacol. Ther. 53: 138. (Abstract.)
11. Cretton, E. M., L. Placidi, and J. P. Sommadossi. 1994. Conversion of AZT to its toxic metabolite AMT is mediated by cytochrome P450 and NADPH-cytochrome C reductase in liver microsomes. Clin. Pharmacol. Ther. 53:189. (Abstract.)
12. Denner, K., R. Vogel, W. Schmalix, J. Doehmer, and R. Bernhardt. 1995. Cloning and stable expression of the human mitochondrial cytochrome P450IIB1 cDNA in V79 Chinese hamster cells and their application for testing of potential inhibitors. Pharmacogenetics 5:89-96.
13. Eagling, V. A., J. L. Howe, M. J. Barry, and D. J. Back. 1994. The metabolism of zidovudine by human liver microsomes in vitro: formation of 3′-amino-3′-deoxythymidine. Biochem. Pharmacol. 48:267-276.
14. Good, S. S., S. C. Koble, R. Crouch, J. L. Rideout, and J. P. de Miranda. 1990. Isolation and characterization of an ether glucuronide of zidovudine, a major metabolite in monkeys and humans. Drug Metab. Dispos. 18:231-236.
15. Howe, J. L., D. J. Back, and J. Colbert. 1992. Extrahepatic metabolism of zidovudine. Br. J. Clin. Pharmacol. 33:190-192.
16. Huang, M. T., E. F. Johnson, U. Muller-Eberhard, D. R. Koop, M. J. Coon, and A. H. Conney. 1981. Specificity in the activation and inhibition by flavonoids of benzo[α]pyrene hydroxylation by cytochrome P-450 isozymes from rabbit liver microsomes. J. Biol. Chem. 256:10897-10901.
17. Huang, M. T., R. L. Chang, J. G. Fortner, and A. H. Conney. 1981. Studies on the mechanism of activation of microsomal benzo[a]pyrene hydroxylation by flavonoids. J. Biol. Chem. 256:6829-6836.
18. Inaba, T., and J. Kovacs. 1989. Haloperidol reductase in human and guinea pig livers. Drug Metab. Dispos. 17:330-333.
19. Irshaid, Y., R. A. Branch, and A. Adedoyin. 1995. Metabolic interactions of putative cytochrome P450 3A substrates with alternative pathways of dapsone metabolism in human liver microsomes. Drag Metab. Dispos. 24:164-167.
20. Kawczynski, W., B. Czochralska, and D. Shugar. 1993. Electrochemical reduction products of azido nucleosides, including zidovudine (AZT): mechanisms and relevance to their intracellular metabolism. Acta Biochim. Pol. 40:213-223.
21. Kerlan, V., Y. Dreano, P. H. Beaune, H. H. Floch, and F. Berthou. 1992. Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. Biochem. Pharmacol. 44:1745-1756.
22. Laaksonen, M., E. Kaliste-Korhonen, S. Karenlampi, and O. Hanninen. 1995. P450 enzyme CYP2B catalyzes the detoxification of diisopropyl fluorophosphate. Chem.-Biol. Interact. 94:197-213.
23. Lee, C. A., K. E. Thummel, S. D. Nelson, and J. T. Slattery. 1991. Inhibition and activation of acetaminophen reactive metabolite formation by caffeine: role of cytochromes P-450 1A1 and 3A2. Drug Metab. Dispos. 19:348-354.
24. Lertora, J. J. L., A. B. Rege, D. L. Greenspan, S. Akula, W. J. George, N. E. Hyslop, and K. Agrawal. 1994. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. 56:272-278.
25. Pan-Zhou, X. R., E. Cretton-Scott, X. J. Zhou, M. X. Yang, J. M. Lasker, and J. P. Sommadossi. 1996. Human liver microsomal cytochrome P450 and b5 act as reductases in the reductive metabolism of 3′-azido-3′-deoxythymidine to 3′-amino-3′-deoxythymidine. Clin. Pharmacol. Ther. 59:168. (Abstract.)
26. Placidi, L., E. M. Cretton, M. Placidi, and J. P. Sommadossi. 1993. Reduction of AZT to 3′-amino-3′-deoxythymidine in human liver microsomes and its relationship to cytochrome P450. Clin. Pharmacol. Ther. 54:168-176.
27. Rajaonarison, J. F., B. Lacarelle, J. Catalin, M. Placidi, and R. Rahmani. 1992. 3′-azido-3′-deoxythymidine drug interactions: screening for inhibitors in human liver microsomes. Drug Metab. Dispos. 20:578-584.
28. Rajaonarison, J. F., B. Lacarelle, A. Durand, and J. Catalin. 1993. In vitro metabolism of zidovudine in man. Therapie 48:341-343.
29. Sahai, J., K. Gallicano, and D. W. Cameron. 1994. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J. Infect. Dis. 169:1103-1107.
30. Sahai, J. 1996. Risks and synergies from drag interactions. AIDS 10(Suppl. 1):S21-S25.
31. Schwab, G. E., J. L. Raucy, and E. F. Johnson. 1988. Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by α-naphthoflavone. Mol. Pharmacol. 33:493-499.
32. Shou, M., J. Grogan, J. A. Mancewicz, K. W. Krausz, F. J. Gonzalez, H. V. Gelboin, and K. R. Korzekwa. 1995. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-6455.
33. Sim, S. M., D. J. Back, and A. M. Breckenridge. 1991. The effect of various drugs on the glucuronidation of zidovudine by human liver microsomes. Br. J. Clin. Pharmacol. 32:17-21.
34. Stagg, M. P., E. M. Cretton, L. Kidd, R. B. Diasio, and J. P. Sommadossi. 1992. Clinical pharmacokinetics of zidovudine and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine. Clin. Pharmacol. Ther. 51:668-676.
35. Tyndale, R. F., T. Inaba, F. J. Gonzalez, J. P. Hardwick, and W. Kalow. 1990. Sparteine metabolism capacity in human liver: structural variants of human P450IID1 as assessed by immunochemistry. Pharmacol. Toxicol. 67:14-18.
36. Waxman, D. J., and C. Walsh. 1983. Cytochrome P-450 isozyme 1 from phenobarbital-induced rat liver: purification, characterization, and interactions with metyrapone and cytochrome bs. Biochemistry 22:4846-4855.
37. Yun, C. H., H. S. Lee, J. K. Rho, H. G. Jeong, and F. P. Guengerich. 1995. Oxidations of the angiotensin receptor antagonist losartan in human liver microsomes, role of cytochrome P450 3A(4) in formation of the active metabolite EXP3174. Drug Metab. Dispos. 23:285-289.
38. Zhou, X. J., and J. P. Sommadossi. 1996. Comparative pharmacokinetics of zidovudine and its toxic catabolite 3′-amino-3′-deoxythymidine in HIV-infected patients. AIDS Res. Hum. Retroviruses 12:229-233.
39. Zhou, X. J., and J. P. Sommadossi. 1994. Quantitation of 3′-amino-3′-deoxythymidine, a toxic catabolite of 3′-azido-3′-deoxythymidine (zidovudine), in human plasma by HPLC using precolumn derivatization with fluorescamine and fluorescence detection. J. Chromatogr. B 656:389-396.